BioSpace News Archive

EV Biologics Corp, OTC PINK:YECO, today updated shareholders about its NFT dividend.

Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing. Sands Capital, Sio Capital and an undisclosed strategic investor joined all existing investors in this financing.

INmune Bio, Inc. announced today that the Company will present a poster at the Alzheimer’s Association International Congress 2021.

Neurana Pharmaceuticals, Inc. today announced participation at the SVB Leerink Biopharma Private Company Connect. The conference takes place virtually July 21st -22 nd.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a distribution agreement with Fosun Pharma for the cPass™ SARS-CoV-2 Neutralizing Antibody Detection Kit* that has received Emergency Use Authorization (“EUA”) from the US FDA for the detection of SARS-CoV-2 receptor binding domain (“RBD” or “neutralizing”) antibodies.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab.

Ascentage Pharma announced that the company has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, part of National Institutes of Health, under which they will collaborate on the non-clinical and clinical development of Ascentage Pharma’s drug compound pelcitoclax.

The presentation identifies a statistically significant effect of ZYESAMI™ in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, announced that the first patient had been dosed in its Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigmentosa.